Atreca, Inc.

ATRECA reported 71 patients treated in the ongoing Phase 1b ATRC-101 trial, including 21 enrolled since the March 2022 update. As of December 31, 2022, the company had $70.5 million in cash, cash equivalents and investments, which it said is expected to fund operations through the end of 2023. For ATRC-101, the company said there were no DLTs up to the 30 mg/kg dose level and no serious adverse events determined to be related to treatment. In the activity analysis, 59% of target-positive monotherapy patients achieved disease control versus 25% of target-negative patients; the reported hazard ratio was 0.47 for monotherapy target-positive versus target-negative patients, and 0.4 when all ATRC-101-treated patients were included. Management did not give company revenue or EPS figures on this call. Forward-lookingly, Atreca said it is targeting 30 to 40 additional patients, expects a go/no-go decision for ATRC-101 Phase 2 by year-end 2023, and plans to nominate clinical candidates for 444 and 958 later this year.

John Orwin framed ATRC-101 as the lead validation of Atreca’s discovery platform, emphasizing that the company is finding antibodies and targets that would be unlikely to emerge through traditional approaches. He stressed that the updated data are encouraging but not yet definitive, and said the team needs more patients and better representation across tumor types before deciding whether and where to advance into Phase 2. His tone was constructive but cautious, with repeated emphasis on the importance of a disciplined go/no-go decision and the opportunity cost of keeping the study open indefinitely.

Herb Cross did not deliver a separate extensive financial segment, but John Orwin relayed the key balance sheet figure: $70.5 million in cash, cash equivalents and investments at December 31, 2022, which management expects to fund operations through the end of 2023. The company also pointed to its patent position, saying it has issued patents covering key aspects of the discovery platform and ATRC-101, with pending applications for other pipeline assets. No revenue, EPS, gross margin or capital allocation details were provided on the call.

Analysts focused on how ATRC-101’s target-enriched strategy would work in practice, asking what percentage of patients meet the H-Score threshold, how the added 30 to 40 patients might differ by tumor type and prior therapy, and what endpoint would drive the Phase 2 decision. Management said prior prevalence work suggested roughly 30% to 50% target expression across indications, and that the new patients would be concentrated at centers better suited to enrolling eligible Phase 2-like patients, with more data expected in lung, breast, head and neck, urothelial and other underrepresented cancers. They said the decision will consider response plus disease control and durability, and noted that monotherapy data remain important for establishing single-agent activity. In other questions, management said it is collecting serial biopsies but has not yet analyzed longitudinal H-Score changes, and clarified that most combination-arm patients entered due to progressive disease or unsatisfactory response on prior PD-1/PD-L1 therapy.